Vizsgálati helyszín
Fundacion Centro Oncologico Regional De Galicia Jose Antonio Quiroga Y Pineyro
A Coruna, 15009, SpanyolországMég nincs intézményhez kötve
- 12futó vizsgálat
- 9lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 21 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis13 vizsgálat
- 2. fázis6 vizsgálat
- 1/2. fázis1 vizsgálat
- 2/3. fázis1 vizsgálat
- Állapot
- Lezárult9 vizsgálat
- Fut, nem toboroz7 vizsgálat
- Toboroz4 vizsgálat
- Még nem toboroz1 vizsgálat
- Fő szponzor
- MedSIR3 vizsgálat
- AstraZeneca2 vizsgálat
- Fundacion Grupo Espanol De Investigacion En Cancer De Mama2 vizsgálat
- H e x a l AG2 vizsgálat
- Ability Pharmaceuticals SL1 vizsgálat
- és még 11
Futó vizsgálatok
Toboroz
Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer
NCT07473128· 3. fázis· Pharmacosmos A/S· Forrás
Toboroz
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
NCT06486883· 2. fázis· MedSIR· Forrás
Toboroz
Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.
NCT06856213· 2. fázis· Grupo Español de Tratamiento de Tumores de Cabeza y Cuello· Forrás
Toboroz
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
NCT06382948· 3. fázis· MedSIR· Forrás
Fut, nem toboroz
A study to continue providing GME751 (a new medicine that is similar to pembrolizumab) to participants who are eligible for pembrolizumab treatment after participation in previous studies (CGME751A12101 or CGME751A12301)
2024-513160-25-00· 3. fázis· H e x a l AG· Forrás
Toboroz
Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging
NCT06276465· 3. fázis· UNICANCER· Forrás
Fut, nem toboroz
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT06082167· 2/3. fázis· Exelixis· Forrás
Fut, nem toboroz
A Study Evaluating Pharmacokinetic similarity between ABP 234 and Keytruda® (pembrolizumab) in Subjects with Early-stage Non-squamous Non-small Cell Lung Cancer as Adjuvant Treatment Following Resection and Platinum-based Chemotherapy
2023-508359-38-00· 3. fázis· Amgen Inc.· Forrás
Fut, nem toboroz
PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin
NCT05810870· 2. fázis· MedSIR· Forrás
Fut, nem toboroz
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
NCT05450692· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
NCT05038735· 3. fázis· Novartis Pharmaceuticals· Forrás
Lezárult
ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study
NCT04431258· 1/2. fázis· Ability Pharmaceuticals SL· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
A study to compare efficacy, safety, and immune response of GME751 and EU-authorized Keytruda in adult participants with untreated metastatic lung cancer
2023-506882-70-00· 3. fázis· H e x a l AG· Forrás
Lezárult
A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered in participants with PD-L1 ≥ 1% TC Stage IIB, IIIA, or select IIIB (T3N2 only) NSCLC following resection and adjuvant platinum-based chemotherapy
2023-506696-10-00· 3. fázis· F. Hoffmann-La Roche AG· Forrás
Fut, nem toboroz
Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer
NCT05403385· 2. fázis· iTeos Therapeutics· Forrás
Lezárult
A phase III trial of trastuzumab + ALpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with PIK3CA mutated previously treated HER2+ Advanced BrEasT cancer. “ALPHABET Study”
NCT05063786· 3. fázis· Fundacion Grupo Espanol De Investigacion En Cancer De Mama· Forrás
Lezárult
The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC
NCT04338399· 3. fázis· Adlai Nortye Biopharma Co., Ltd.· Forrás
Leállították
Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)
NCT04428151· 2. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer
NCT04305496· 3. fázis· AstraZeneca· Forrás
Lezárult
Clinical trial to compare the efficacy and tolerability of fulvestrant (FaslodexTM) 500mg with placebo versus fulvestrant (FaslodexTM) 500mg with PD-0332991 (Palbociclib), randomly assigned, as first line treatment for postmenopausal women with hormone receptor-positive metastatic breast cancer, who have completed at least 5 years of hormonal therapy and remained disease free for more than 12 months following its completion or who have metastatic disease diagnosed from the beginning.
2024-516132-10-00· 2. fázis· Fundacion Grupo Espanol De Investigacion En Cancer De Mama· Forrás
Lezárult
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
NCT02486718· 3. fázis· Hoffmann-La Roche· Forrás
Hibát jelzek